Skip to main content

Table 3 Multivariate analysis of predictors for PFS

From: Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: the largest multicenter retrospective analysis of survival and prognostic factors

Variables

 

P

HR

95.0% CI

Lower

Upper

Drug

Sorafenib vs Sunitinib

<0.001

1.420

1.211

1.664

Gender

Male vs Female

0.414

1.074

0.906

1.273

Age

<65 vs > =65

0.194

0.879

0.723

1.068

Pathology

Clear cell vs Non clear cell

0.024

1.312

1.037

1.660

ECOG

0 vs 1 vs 2 vs 3

<0.001

1.245

1.105

1.402

Previous nephrectomy

No vs Yes

0.500

0.931

0.755

1.147

MSKCC

Low vs median vs High

0.043

1.253

1.007

1.558

HENG

Low vs median vs High

<0.001

1.458

1.198

1.774

Number of metastatic organs

1 vs 2 vs 3 vs 4

0.679

1.033

0.886

1.204

Lung metastasis

Yes vs No

0.175

1.173

0.931

1.478

Single lung metastasis

No vs Yes

0.188

0.834

0.637

1.092

Bone metastasis

Yes vs No

0.108

1.193

0.962

1.481

Single bone metastasis

No vs Yes

0.085

0.703

0.470

1.050

Liver metastasis

Yes vs No

<0.001

1.645

1.263

2.142

Lymph node metastasis

Yes vs No

0.023

1.250

1.031

1.516

Second line treatment

No vs Yes

<0.001

1.398

1.184

1.651